Boehringer Ingelheim, the German pharmaceutical company and contract manufacturer, will close its entire Ben Venue Laboratories operation in Bedford, Ohio, by the end of 2013.
Boehringer has struggled to keep the Ohio site open after a series of drug quality problems and has been operating since January under a consent decree with FDA but ultimately decided that given the facility’s age and condition, further improvements would require too much additional investment.
The closure will affect 1,100 employees.
